Clinical correlates of early medication adherence: West London first episode schizophrenia study

Acta Psychiatrica Scandinavica

Volumn 108, Issue 6, 2003, Pages 439-446

  Mutsatsa, S H ^a,c   Joyce, E M ^a   Hutton, S B ^b   Webb, E ^a   Gibbins, H ^a   Paul, S ^a   Barnes, T R E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; First episode schizophrenia; Medication adherence

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MONITORING; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FORECASTING; HOSPITALIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PARKINSONISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGY; RESIDENTIAL CARE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SUBSTANCE ABUSE; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CATCHMENT AREA (HEALTH); FEMALE; FORECASTING; HUMANS; LONDON; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 0344874179     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0001-690X.2003.00193.x     Document Type: Article

References (56)

1. ALTAMURA A, MALHI GS. Compliance in major psychoses. Int J Psychiatry Clin Pract 2000;4:81-82.
2. BEBBINGTON PE. The content and context of compliance. Int Clin Psychopharmacol 1995;9(Suppl. 5):41-50.
3. FRANGOU S, BYRNE P. How to manage the first episode of schizophrenia. BMJ 2000;321:522-523.
4. ROBINSON D, WOERNER MG, ALVIR JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247.
5. VERDOUX H, LENGRONNE J, LIRAUD F et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2000;102:203-210.
6. KAMPMAN O, LEHTINEN K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-175.
7. BARNES TRE, HUTTON SB, CHAPMAN MJ, MUTSATSA S, PURI BK, JOYCE EM. West London first-episode study of schizophrenia. Clinical correlates of duration of untreated psychosis. Br J Psychiatry 2000;177:207-211.
8. TEHRANI E, KRUSSEL J, BORG L, MUNK-JORGENSEN P. Dropping out of psychiatric treatment: a prospective study of a first-admission cohort. Acta Psychiatr Scand 1996;94:266-271.
9. KOVASZNAY B, FLEISCHER J, TANENBERG-KARANT M, JANDORF L, MILLER AD, BROMET E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997;23:195-201.
10. STRAKOWSKI SM, KECK PE JR, MCELROY SL et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 1998;55:49-55.
11. KAMPMAN O, LAIPPALA P, VAANANEN J et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002;110:39-48.
12. COLDHAM EL, ADDINGTON J, ADDINGTON D. Medication adherence of individuals with a first episode psychosis. Acta Psychiatr Scand 2002;106:286-290.
13. KEMP R, KIROV G, EVERITT B, HAYWARD P, DAVID A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998;172:413-419.
14. HUTTON SB, PURI BK, DUNCAN LJ, ROBBINS TW, BARNES TRE, JOYCE EM. Executive function in first-episode schizophrenia. Psychol Med 1998;28:463-473.
15. HUTTON SB, CRAWFORD TJ, PURI BK et al. Smooth pursuit and saccadic abnormalities in first-episode schizophrenia. Psychol Med 1998;28:685-692.
16. ANDREASEN NC. Scale for Assessment of Negative Symptoms. 1981. Iowa: University of Iowa.
17. ANDREASEN NC, Methods for assessing positive and negative symptoms. In: ANDREASEN NC, eds. Schizophrenia: positive and negative syndromes: modern problems in Pharmacopsychiatry, Basel: Karger, Vol. 24, pp. 73-85.
18. HAYWARD P, CHAN N, KEMP R, YOULE S, DAVID A. Medication self management: a preliminary report on an intervention to improve medication compliance. J Ment Health 1995;4:511-517.
19. WEIDEN P, RAPKIN B, MOTT T et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310.
20. DAVID A, BUCHANAN A, REED A, ALMEIDA O. The assessment of insight in psychosis. Br J Psychiatry 1992;161:599-602.
21. DAY JC, WOOD G, DEWEY M, BENTALL RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166: 650-653.
22. LINGJAERDE O, AHLFORS UG, BECH P, DENCKER SJ, ELGEN K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(Suppl. 334):1-100.
23. NABER D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl. 3): 133-138.
24. GUY W. Assessment manual for psychopathology, revised edn. Washington, DC: Department of Education, Health and Welfare, 1976:534-537.
25. SIMPSON G, ANGUS J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
26. BARNES TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
27. SCHOOLER NR, KANE JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
28. DUKE PJ, PANTELIS C, BARNES TRE. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994;164:630-636.
29. LIDDLE PF, BARNES TRE. Syndromes of chronic schizophrenia. Br J Psychiatry 1990;157:558-561.
30. GUR RE, PETTY RG, TURETSKY BI, GUR RC. Schizophrenia throughout life: sex differences in severity and profile of symptoms. Schizophr Res 1996;21:1-12.
31. BUCHANAN A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-797.
32. WEIDEN P, DIXON L, APPELBAUM P et al. Noncompliance in schizophrenia. In: TAMINGA C, SHULTTZ SC, eds. Advances in neuropsychiatry and psychopharmacology, New York: Raven Press, 1991:285-296.
33. RUSCHER SM, DE WIT R, MAZMANIAN D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr Serv 1997;48:82-85.
34. ADAMS SG JR, HOWE JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993;181:558-560.
35. DONOHOE G, OWENS N, O'DONNELL C, BURKE T, MOORE L, TOBIN A, O'CALLAGHAN E. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001; 16:293-298.
36. BECKER MH, MAIMAN LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975;13:10-24.
37. BUDD RJ, HUGHES IC, SMITH JA. Health beliefs and compliance with antipsychotic medication. Br J Clin Psychol 1996; 35:393-397.
38. HUGHES I, HILL B, BUDD RJ. Compliance with antipsychotici medication: from theory to practice. J Ment Health 1997 ;473-489.
39. MCEVOY JP, APPLEBAUM PS, APPERSON LJ, GELLER JL, FRETER S. Why must some schizophrenic patients be involuntarily committed? The role of insight. Compr Psychiatry 1989; 30:13-17.
40. DAVID A, VAN OS J, JONES P, HARVEY I, FOERSTER A, FAHY T. Insight and psychotic illness. Cross-sectional and longitudinal associations. Br J Psychiatry 1995;167:621-628.
41. ADAMS J, SCOTT J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 2000;101:119-124.
42. BECK-SANDER A. Is insight into psychosis meaningful? J Ment Health 1998;7:25-34.
43. DAVID A. Commentary on: is insight into psychosis meaningful? J Ment Health 1998;7:579-583.
44. APPELBAUM PS, GUTHEIL TG. Drug refusal: a study of psychiatric inpatients. Am J Psychiatry 1980;137:340-346.
45. MARDER SR, MEBANE A, CHIEN CP, WINSLADE WJ, SWANN E, van PUTTEN T. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983; 140:470-472.
46. AGARWAL MR, SHARMA VK, KISHORE KUMAR KV, LOWE D. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998;44:92-106.
47. van PUTTEN T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
48. YOUNG DA, DAVILA R, SCHER H. Unawareness of illness and neuropsychological performance in chronic schizophrenia. Schizophr Res 1993;10:117-124.
49. TRAN PV, DELLVA MA, TOLLEFSON GD, BEASLEY CM JR, POTVIN JH, KIESLER GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;8:205-211.
50. SELLWOOD W, TARRIER N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1994;29:172-177.
51. BARNES TRE, MCPHILLIPS MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998;13(Suppl 3):S49-S57.
52. NABER D, MORITZ S, LAMBERT M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
53. BARNES TRE, MCPHILLIPS MA. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psychopharmacol 1995;10(Suppl 3):115-121.
54. DRAKE RE, WALLACH MA, HOFFMAN JS. Housing instability and homelessness among aftercare patients of an urban state hospital. Hosp Community Psychiatry 1989;40: 46-51.
55. OWEN RR, FISCHER EP, BOOTH BM, CUFFEL BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47:853-858.
56. PRISTACH CA, SMITH CM. Medication compliance and substance abuse among schizophrenic patients. Hosp Community Psychiatry 1990;41:1345-1348.